BGNE241220P150000
- 0.55
- 0.000.00%
BeiGene Newsroom
Beigene (06160.HK) obtained 0.4931 million shares of restricted stock units due to the restricted share units.
Gelonghui December 2 | Beigene (06160.HK) announced that on November 30, 2024, 0.4931 million shares of common stock will be issued due to the vested restricted stock units granted under the equity plan (excluding the company's directors).
Weilizhizhi is applying to list on the Hong Kong Stock Exchange, positioning itself as a leader in the development of next-generation tumor immunotherapy.
Currently, the heat and activity of the bispecific antibody track are rapidly rising, and it has become a new hot spot in the global innovative drugs industry. Multinational pharmaceutical companies are actively "sweeping the shelves", actively seeking and investing in promising bispecific pipelines. According to the statistics of Bioon, in the first three quarters of 2024, global pharmaceutical companies' transaction activities in the field of bispecific drugs were exceptionally active, with a total of 31 transactions completed. This number exceeds the total annual transaction volume of any year in the past three years, enough to show that the status and influence of bispecific drugs in the global pharmaceutical market are rapidly rising. Among them, there were 5 large BD transactions on bispecific/trispecific drugs in November alone, with high amounts involved.
Insider Sale: Director at $BGNE (BGNE) Sells 200 Shares
Bernstein Maintains BeiGene(BGNE.US) With Hold Rating, Raises Target Price to $207
Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading
BeiGene's Four Drugs Included in China's Medical Insurance Catalog; Shares Jump 5%
Analysts Offer Insights on Healthcare Companies: BeiGene (BGNE) and Teladoc (TDOC)
Top Gap Ups and Downs on Wednesday: SONY, DELL, ADSK and More
Why Is BeiGene Stock Trading Higher On Wednesday?
Sector Update: Health Care Stocks Rise Pre-Bell Wednesday
European Commission Approves Products by BeiGene, GSK and Novartis
Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Wednesday Ahead of Crucial Inflation Data
BeiGene's Gastric, Esophageal Cancer Treatment Gets EU Approval
Express News | The European Commission Has Approved BeiGene's Tevimbra (Tislelizumab) In Combination With Chemotherapy For The First-line Treatment Of Esophageal Squamous Cell Carcinoma And Gastric Or Gastroesophageal Junction Adenocarcinoma
European Commission Approves BeiGene's TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer
Express News | European Commission Approves Beigene’s Tevimbra for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer
National medical insurance drug list unveiling soon! Keji Pharmaceutical's stock surged over 9%, leading the way in Hong Kong pharmaceutical stocks.
1. What is the importance of centralized procurement of pharmaceutical companies by medical insurance? 2. Which areas of products are expected to be included in the 2024 National Medical Insurance Drug Catalog?
Beigene issued approximately 0.5 million shares due to the exercise of stock options.
Beigene (06160) announced that the company will issue approximately 0.5 million shares on November 26, 2024, due to a director exercising stock options.
Beigene (06160.HK) exercised the right to purchase shares and issued 0.5 million shares.
Beigene (06160.HK) announced on November 27 that approximately 0.5 million ordinary shares were issued due to a director exercising stock options on November 26, 2024.
BeiGene to Present at Upcoming Investor Conferences